The case report is the first to present a dramatic autoimmune disorder following cancer immunotherapy characterized by multiple specific autoantibodies, including anti-GBM, PR3, MPO, dsDNA, PL-7 and Ku antibodies, without notable clinical involvement. Here, PRTN3 is linked to cancer.